Molecular Gene Cloning and Nucleotide Sequencing and Construction of an *aroA* Mutant of *Pasteurella haemolytica* Serotype A1

FRED M. TATUM,^{1*} ROBERT E. BRIGGS,² AND SHIRLEY M. HALLING¹

Brucellosis Research Group¹ and Pasteurellosis Research Group,² National Animal Disease Center, Agricultural Research Center, U.S. Department of Agriculture, Ames, Iowa 50010

Received 3 December 1993/Accepted 3 April 1994

The *aroA* gene of *Pasteurella haemolytica* serotype A1 was cloned by complementation of the *aroA* mutation in *Escherichia coli* K-12 strain AB2829. The nucleotide sequence of a 2.2-kb fragment encoding *aroA* predicted an open reading frame product 434 amino acids long that shows homology to other bacterial AroA proteins. Several strategies to inactivate *aroA* were unsuccessful. Gene replacement was finally achieved by constructing a replacement plasmid with *aroA* inactivated by insertion of a *P. haemolytica* ampicillin resistance fragment into a unique *NdeI* site in *aroA*. A hybrid plasmid was constructed by joining the *aroA* replacement plasmid with a 4.2-kb *P. haemolytica* plasmid which encodes streptomycin resistance. Following *PhaI* methylation, the replacement plasmid was introduced by electroporation into *P. haemolytica* NADC-D60, a plasmidless strain of serotype 1A. Allelic exchange between the replacement plasmid and the chromosome of *P. haemolytica* gave rise to an ampicillin-resistant mutant which grew on chemically defined *P. haemolytica* medium supplemented with aromatic amino acids but failed to grow on the same medium lacking tryptophan. Southern blot analysis confirmed that *aroA* of the mutant was inactivated and that the mutant was without a plasmid.

The microorganism *Pasteurella haemolytica* biotype A, serotype 1, is the principal causative agent of pneumonic pasteurellosis in cattle. With the development of techniques for introducing exogenous DNA into *P. haemolytica* (5), it now may be possible to produce site-specific mutations in this bacterium. Such mutants would prove extremely useful in investigating the molecular mechanisms of pathogenesis of *P. haemolytica*. Also, genetic manipulation of *P. haemolytica* may permit construction of rationally attenuated strains to test as live vaccine candidates.

Attenuated auxotrophic mutants were first described by Bacon et al. in 1950 (3). In that study, it was reported that attenuated auxotrophs of Salmonella typhi defective in the aromatic amino acid biosynthetic pathway were avirulent in mice. Subsequently, it has been demonstrated in widely diverse bacteria that disrupting the aromatic amino acid biosynthetic pathway produces attenuated organisms. For example, attenuated strains of the invasive bacteria S. typhi (3), Salmonella typhimurium (11), Shigella flexneri (22), and Yersinia enterocolitica (4) were generated by introducing mutations in their respective aroA genes. Also, attenuation was produced in the noninvasive bacteria Bordetella pertussis (19) and Pasteurella multocida (13) through aroA inactivation. These aroA mutant strains are unable to synthesize chorismic acid from which p-aminobenzoic acid, dihydrobenzoate, and aromatic amino acids are produced. It is likely that the absence of one or more of these compounds in vivo is responsible for the poor growth of aroA mutants in the hosts.

The interest in constructing attenuated bacterial strains as vaccine candidates can be attributed to the superior protection afforded by live vaccines. In general, live vaccines elicit a stronger cell-mediated response in the host than do bacterins (7). Also, the superior immunity provided by attenuated organisms compared with that provided by killed bacteria may be explained by induced expression of stress proteins and, possibly, of certain toxins within the host. The immune response generated by live organisms would be directed against these abundant proteins and thereby provide better protection.

Because most vaccines to prevent pneumonic pasteurellosis are killed formulations, we decided to construct an *aroA* mutant of *P. haemolytica* to test for efficacy as a live vaccine. To accomplish this goal, we cloned and determined the nucleotide sequence of *P. haemolytica aroA*. A number of replacement plasmids and hybrid plasmids consisting of a replacement plasmid joined to plasmids of *P. haemolytica* were constructed. Following methylation by *PhaI* methyltransferase, the plasmids were introduced into *P. haemolytica*. One of these constructs, a hybrid plasmid which joined the replacement plasmid harboring insertionally inactivated *aroA* to the *P. haemolytica* plasmid encoding streptomycin resistance, was used to produce an *aroA* mutant by gene replacement.

MATERIALS AND METHODS

Molecular cloning and Southern blot analysis of P. haemolytica aroA. Genomic DNA was prepared from P. haemolytica NADC-D60 by previously described methods (5). Southern blotting of P. haemolytica restriction fragments fractionated by electrophoresis on 0.75% agarose was performed as described previously (5). Blots were hybridized with a radioactively labeled 1.3-kb Escherichia coli aroA fragment. The aroA probe was amplified (Gene-AMP; Perkin-Elmer Inc., Branchburg, N.J.) from E. coli X-L1 Blue (Stratagene, Inc., La Jolla, Calif.) genomic DNA by PCR. The primers (5'-AGGCTGCCTG GCTAATCCGCGCCAG-3' and 5'-TTCATGGAATCCCTT GACGTTACAACCCATC-3') used in the PCR hybridize with E. coli aroA nucleotides 1308 through 1332 and to the complementary strand of nucleotides -3 through 28, respectively. The primers were synthesized with an oligonucleotide synthesizer (Applied Biosystems Inc.) by the Nucleic Acids Facility, Iowa State University, Ames. DNA was radiolabeled with $[\alpha^{-32}P]dCTP$ with a random-priming kit (Boehringer Mannheim Biochemicals, Indianapolis, Ind.). Nylon membranes (Hybond-N; Amersham Corp., Arlington Heights, Ill.) were

^{*} Corresponding author. Phone: (515) 239-8200. Fax: (515) 239-8458.

2012 TATUM ET AL.

Strain or plasmid	Characteristic(s)	Source or reference
Strains		
E. coli		
AB2829	K-12 strain with mutation in aroA	18
DH10B	Cloning strain used in this work	BRL
<i>Pha</i> IMtase	Recombinant DH108B carrying PhaI methyltransferase gene on cosmid vector	This work
S17-1	Donor strain containing chromosomally integrated RP4 transfer functions	20
XL1-Blue	Strain used for DNA sequencing	Stratagene
P. haemolytica		
NADC-D60	Serotype 1, plasmidless	NADC ^a (R. Briggs)
NADC-D70	Serotype 1 containing pD70	NADC (R. Briggs)
NADC-D80	Serotype 1 containing pD80	NADC (R. Briggs)
Plasmids		
pSK	Cloning vector (Amp ^r)	Stratagene
pBC SK	Cloning vector (Cm ^r)	Stratagene
pD70	4.2-kb plasmid encoding Sm ^r	NADC (R. Briggs)
pD80	4.2-kb plasmid encoding Amp ^r	NADC (R. Briggs)
pPharoA1	3.2-kb HindIII fragment containing P. haemolytica aroA (pSK)	This work
pPharoA2	HindIII-ClaI digest of pPharoA1 resulting in 2.2-kb aroA fragment (pSK)	This work
pPharoA3	Same insert as pPharoA2 on pBC SK	This work
pPh∆ <i>aroA</i> Cm ^r	StyI-NdeI digest of pPharoA2 Cm ^r fragment inserted into deletion site	This work
pPh∆ <i>aroA</i> Cm ^r pD80	SmaI-digested pPh $\Delta aroACm^r$ joined to ScaI-digested pD80	This work
pPhAmp ^r	2.2-kb Sau3A fragment of pD80 cloned into pBC SK	This work
pPharoA ⁻ Amp ^r	Amp ^r fragment of pD80 inserted into unique NdeI site of pPharoA3	This work
pPharoA ⁻ Amp ^r pD70	HindIII-digested pPharoA ⁻ Amp ^r joined to HindIII-digested pD70	This work

TABLE 1. Bacterial strains and plasmids up

" NADC, National Animal Disease Center, Ames, Iowa.

incubated with a prehybridization solution of $5 \times SSC$ (1× SSC is 0.15 M NaCl and 0.015 M sodium citrate), $5 \times$ Denhardt's solution (15), 0.1% sodium dodecyl sulfate (SDS), 10 µg of sonicated salmon sperm DNA per ml, and 50% formamide at 42°C for 2 h. After removal of the prehybridization solution, the filters were incubated with hybridization solution (same as the prehybridization solution but lacking Denhardt's solution) containing 10⁷ cpm of ³²P-labeled probe and 50% formamide at 42°C. After hybridization for 18 h, membranes were washed twice with 1× SSC–0.1% SDS for 10 min each time at room temperature and two times with 1× SSC–0.1% SDS buffer at 42°C for 15 min each time. Membranes were exposed to X-AR (Eastman Kodak Co., Rochester, N.Y.) at $-80^{\circ}C$ for 24 h. A positive signal corresponding to a 3.2-kb *Hind*III fragment of *P. haemolytica* chromosomal DNA was identified.

HindIII-digested P. haemolytica DNA fragments ranging from 3.0 to 3.4 kb in length were electroeluted from a 1% agarose gel. The HindIII genomic fragments were added to HindIII-digested alkaline phosphatase-treated pBluescript SK⁻ vector (Stratagene, Inc.) and ligated overnight at 10°C with T4 ligase (Bethesda Research Laboratories [BRL], Gaithersburg, Md.). The ligation mix was diluted 1:10 with distilled water and electroporated with a Gene Pulser (Bio-Rad Laboratories, Richmond, Calif.) into E. coli aroA mutant AB2829 (18). A recombinant plasmid, pPharoA1, complemented AB2829 growth on M9 minimal medium containing phosphate buffer, 1 mM MgSO₄, 0.1 mM CaCl₂, 0.2% glucose, thiamine (10 µg/ml), 1.5% Noble agar (Difco), and 50 µg of ampicillin per ml (1). ClaI-HindIII double digestion of pPHaroA1 produced a 2.2-kb fragment which when cloned into the AccI and HindIII sites of pBluescript SK⁻ gave rise to pPharoA2. The recombinant plasmid, pPharoA2, which also complemented growth of AB2829 on minimal plates, was used to sequence P. haemolytica aroA. Plasmid pPharoA3 was generated by subcloning the 2.2-kb fragment of pPharoA2 into pBC SK+ (Stratagene Inc.).

DNA sequencing and analysis. DNA sequencing was done

by the dideoxy nucleotide termination method with single- or double-stranded templates by using the Sequenase 2.0 kit (United States Biochemicals, Cleveland, Ohio). A series of ordered deletions were made in *P. haemolytica aroA* on pPHaroA2 by using an Erase-a-Base kit (Promega Corp., Madison, Wis.). Gaps in the sequence were completed by using DNA primers synthesized by the DNA Core Facility at Iowa State University. DNA sequence analysis was done with MacDNASIS Pro (Hitachi Software Ltd., San Bruno, Calif.) and MacVecvtor (Kodak Co., New Haven, Conn.) software.

Construction of replacement plasmids and the production and characterization of a *P. haemolytica aroA* mutant. Construction of the replacement plasmid pPh $\Delta aroA$ Cm^r (Table 1) and the hybrid plasmid pPh $\Delta aroA$ Cm^r pD80 is described in the preceding study (5). The steps involved in the construction of the other plasmids used in this study (Table 1) are presented below.

Plasmid pD80, a 4.2-kb ampicillin resistance (Amp^r) encoding plasmid of P. haemolytica (2, 14), was partially digested with Sau3A and ligated into the BamHI site of pBC SK⁺ (Stratagene Inc.). The ligation mix was diluted 1:10 in distilled water and electroporated into E. coli DH-10B (BRL). After recovery in 1 ml of SOC medium containing 2% Bacto Tryptone, 0.5% Bacto Yeast Extract, 8 mM NaCl, 2.5 mM KCl, 10 mM MgCl₂, and 20 mM glucose (15), at 37°C the cells were spread onto B-broth plates, containing 1% Bacto Tryptone, 0.8% NaCl, 2% Difco agar, thiamine (10 µg/ml), 0.002% 5-chloro-4-bromo-3-indolyl- β -D-galactopyranoside (X-Gal), 100 μ M isopropyl- β -D-thiogalactopyranoside (IPTG), and 50 µg of ampicillin per ml. Plasmid pPhAmp^r contained a 2.2-kb P. haemolytica fragment which imparted ampicillin resistance to E. coli to up to 100 µg/ml. Plasmid pPhAmp^r was digested with HindIII and XbaI, and the fragment ends were made blunt by incubation with deoxynucleoside triphosphates and the large Klenow fragment of E. coli polymerase I. The fragment encoding ampicillin resistance was electroeluted and used to inactivate aroA of pPharoA3. To do so, pPharoA3 was digested

at a unique NdeI site contained in aroA (see Fig. 2) and the fragment ends were made blunt as described above. The ampicillin resistance fragment was blunt end ligated with pPharoA3 to generate pPharoA⁻Amp^r. To produce a hybrid plasmid, pPharoA - Ampr was digested with HindIII and dephosphorylated with calf alkaline phosphatase. A 4.2-kb plasmid, designated pD70, which encodes streptomycin resistance (Sm^r) (6), was isolated from *P. haemolytica* NADC-D70 by previously described methods. Plasmid pD70 was digested at a unique HindIII recognition site and ligated with HindIIIdigested pPharoA Ampr to generate the hybrid plasmid pPharoA - AmprpD70. Plasmid pPharoA - AmprpD70 was electroporated into E. coli PhaIMtase (Table 1). Strain PhaIMtase is E. coli DH-10B (BRL) which contains the PhaI methyltransferase gene on cosmid vector pLAFRX, which was derived from pLAFR2 (9). Then the PhaI methyl-modified hybrid plasmid was isolated by the alkaline lysis method (15) and CsCl purified. One microgram of plasmid and 100 µl of P. haemolytica NADC-D60 (a plasmidless isolate of serotype A1) were transferred to a 0.1-cm cuvette and electroporated at 15,000 V/cm with 800 Ω . The resultant time constant was approximately 9 mc. Cells were transferred to 1 ml of Bacto Columbia broth (Difco Labs, Detroit, Mich.) and incubated at 37°C for 1 h. One milliliter of Columbia broth containing 20 µg of ampicillin was added, and the cells were incubated for an additional hour and then spread on Difco Columbia blood agar plates containing 5% bovine blood and 10 µg of ampicillin per ml. Eight ampicillin-resistant P. haemolytica colonies were isolated after incubation at 37°C for 18 h. The colonies were then transferred to Bacto Columbia broth containing 1 µg of ampicillin per ml and incubated at 37°C. Daily passage into fresh medium containing 1 µg of ampicillin per ml was carried out for 3 days, at which time the cultures were transferred onto Columbia broth blood agar plates containing 10 µg of ampicillin per ml and incubated at 37°C overnight. The next day the colonies were replica plated onto Columbia broth blood agar plates containing 10 μ g of chloramphenicol per ml or 50 μ g of streptomycin per ml. The colonies were also replica plated onto a chemically defined medium for P. haemolytica cultivation (23). The defined medium contained 15 amino acids and included the aromatic amino acids phenylalanine and tyrosine but not tryptophan. Clones unable to grow on the chemically defined medium for P. haemolytica cultivation were presumed to be aroA mutants. Genomic DNAs isolated from clones with Amp^r Cm^s Sm^s AroA⁻ phenotypes were analyzed by Southern blotting. Southern blotting was performed as described previously with the exception that after hybridization the membranes were washed twice for 10 min each in $1 \times$ SSC-0.1% SDS at 42°C and twice more for 15 min each in $0.1 \times$ SSC-0.1% SDS at 65°C.

Nucleotide sequence accession number. The *P. haemolytica* aroA sequence data reported here have been deposited in GenBank under accession number U03068.

RESULTS AND DISCUSSION

Cloning of *P. haemolytica aroA.* Restriction fragments of *P. haemolytica* genomic DNA were fractionated by agarose gel electrophoresis. The fragments were probed for homology to *E. coli aroA* by Southern analysis. Under conditions of low stringency, a 3.2-kb *Hind*III fragment of *P. haemolytica* genomic DNA hybridized with radiolabeled *E. coli aroA* (Fig. 1). The *Hind*III fragment was isolated from an agarose gel by electroelution and was cloned into *Hind*III-digested pBluescript SK⁻. The recombinant plasmid, pPHaroA1, bearing *P. haemolytica aroA* was identified by complementation of *E. coli*



FIG. 1. Southern blot analysis of *P. haemolytica* NADC-D60 DNA digested with *Eco*RI (lane 1), *Cla*I (lane 2), *Pst*I (lane 3), or *Hind*III (lane 4). The membrane was hybridized with an *E. coli aroA* probe, and washing was performed under low-stringency conditions.

aroA mutant AB2829 on M9 minimal medium containing ampicillin. A *ClaI-HindIII* double digest of pPharoA1 generated a 2.2-kb fragment which was cloned into the *AccI* and *HindIII* sites of pBluescript SK⁻, giving rise to pPharoA2. Plasmid pPharoA2 also complemented growth of *E. coli* AB2829 on M9 minimal medium. Plasmid pPharoA2 was used to determine the nucleotide sequence of *P. haemolytica aroA* presented here.

Nucleotide sequence and analysis of *P. haemolytica aroA*. The nucleotide sequence and the deduced amino acid sequence of *P. haemolytica aroA* and its product are shown in Fig. 2. Sequence analysis on *P. haemolytica aroA* revealed an open reading frame of 1,302 bases with a coding capacity of 434 amino acid residues. The deduced molecular weight is 47,296, and the G+C content of the *aroA* coding region product is 43%. The predicted amino acid sequence of *P. haemolytica* AroA showed 75, 70, 69, and 68% identity with the AroA proteins of *P. multocida* (13), *Klebsiella pneumoniae* (21), *Y. entercolitica* (17), and *E. coli* (8), respectively.

P. haemolytica aroA, like *P. multocida aroA* (13), appears to be transcribed from its own promoter. This differs from the usual genetic arrangement in gram-negative bacteria, in which *aroA* and *serC* constitute an operon with *aroA* distal to the promoter (8, 12, 17). Evidence to support this claim includes the findings that (i) the nucleotide sequence upstream of *aroA* on clone pPharoA2 shows no homology with *serC* genes and (ii) complementation of *E. coli* AB2829 by *P. haemolytica aroA* contained on the 2.2-kb fragment is independent of the fragment's orientation on the cloning vector (data not shown).

Construction of a *P. haemolytica aroA* **mutant.** The purpose of this investigation was to develop methods in order to genetically engineer a rationally attenuated strain of *P. haemolytica*. To achieve this goal, a number of replacement plasmids were constructed, each considered an improvement on the previous one which failed to produce an *aroA* mutant. First the deletion plasmid pPh $\Delta aroACm^r$ (Table 1) was constructed from pPharoA2 as described previously (5) and amplified in *E. coli PhaIMtase*. Although resistant to *PhaI* digestion (data not shown), introduction of pPh $\Delta aroACm^r$ into *P. haemolytica* NADC-D60 by electroporation failed to generate Cm^r colonies. The inability to transform *P. haemolytica* with pPh $\Delta aroACm^r$ indicated that plasmids containing a ColE1 origin do not replicate in this bacterium.

30 TATGAGGCATTACTGCGTGAAGGCGTGATTGTTCGCTCGATAGCA												GT	FAT	GA	NTG	60 CCG2	AAT	CAT	TTA	ccc.	ATT	AGT	ATG	CCT	TA	90 CCG			
~~~	~~~		~~~		_		3.05	~~~	120			~ ***		~~~				-	150	n mm	**	CAA		ጥጥጥ	202	እእጥ	ጥጥል	AG	180 AGA
CAA	unn	nnc	3733	nun		***	ACT	GUU		110		919	1100		1.1.1.														
									210										240									1	270
хаа	ATG	GAA	777 	CTA	ACT	TTA	ACC	cce	ATT	TCO	CGA	GTA	GAN	çço	GAG	ATC	AAT:	FTA T	CCI	GT	TCT.	AAA	NGC	CIG	TCT	AAC	CGA	SCC.	TTA
	M	E	ĸ	г	т	ь	T	P	1	S	R	v	E	G	E	1	N	Г	r 220	G	3	r	3	ц	3	N	r	٦.	360
тта	ጥጥ እ		600	тта	600	200	GGT	100	300 300	~~~	GTG	ACC	ידגג	тта	<b>TT M</b>	-	AGTO		GAT	ATT	CGA	CAT	ATG	CTC	АЛТ	GCC	TTA		GCG
L	L	A	A	L	A	T	G	T	T	2	v	T	N	L	L	D	S	D	D	I	R	H	M	L	N	A	L	ĸ	A
									390										420										450
TTA	GGC	GTG	AAA	TAT	GAG	CTA	TCG	GAC	GAT	XXX	<b>ACO</b>	GTC	TGT	GTA	CTT	GAA	GGGI	ATT	GGT	GGA	GCT	TTT	AAG	GIT	CAA	ANC.	GCC:	TA'	TCA
L	G	v	ĸ	Y	E	L	s	D	D	ĸ	т	v	с	v	L	E	G	I	G 61.0	G	A	F	ĸ	v	Q	N	G	Ľ	540
CTG		~~~~	ccc		<b>~~</b> >	ccr	200	CC 2	480 370	<b>~~</b> 2	<b>CC3</b>	CTT	CC.N	CC.	CA	rTG'	TGT	гта	AAA	GGT	GAG	GAA		тсс	СЛА	ATC	ATT	TT	ACC
L	F	L	G	N	A	G	T	A	M	R	P	L	λ	A	λ	L	с	L	ĸ	G	E	E	ĸ	S	õ	I	I	L	T
									570										600										630
GGT	GAA	CCA	AGA	ATG	AAA	GAA	CGC	CCG	ATT	<b>XXX</b>	CVC	TTA	GTC	GAT	GCT	TTA	CGC	CAA	GTM	GGG	GCA	CYC	GTA	CAG	TAT	TTA	GYY	AT .	GAA
G	E	P	R	М	ĸ	Е	R	P	I	ĸ	H	L	v	D	A	L	R	õ	v 600	G	A	E	v	Q	x	г	E	N	E 720
GGC			ccc	TTG	<u></u>	ልጥጥ	ACC	3 <b>3</b> T	100	ርጥጥ	TGC	AGG	660	GGA		CTC	CAN	ATT	GAC	GGC	TCG	ATT	TCC	AGC	саа	TTT	CTA	١cc	GCA
G	Y	P	P	L	A	I	S	N	s	v	с	R	G	G	R	v	0	I	D	G	S	I	s	s	Q	F	L	T	A
									750										780										810
TTG	CTG	ATG	TCT	GCC	CCA	TTA	acce	GYY	.ccc	GAT	ATG	GYY	ATT	GVC	ATT.	ATC	GGT	GAT	CIC	GTA	TCA	<u>ллл</u>	CCT	TAT	ATT	GAT	ATT:	<u>م</u>	CTT
Ľ	L	м	S	A	P	L	A	E	G	D	M	E	I	E	I	I	G	D	г	v	s	ĸ	P	I	Ŧ	D	Ŧ	T	ъ
									840										870										900
TCG	ATG	ATG	AAC	GAT	TTT	GGT	ATT	ACG	840 GTT	GAA	AAT	CGA	GAT	TAC	***	ACC	TTT	TTA	870 GTT	<b>, , , ,</b>	GGT	***	CYY	2223	TAT	GTT	CT O	CA.	900 CAA
TCG S	atg M	ATG M	aac N	GAT D	TTT F	GGT G	'ATT I	ACG T	840 GTT V	GAA E	AAT N	CGA R	GAT D	TAC Y	AAA K	ACC T	TTT F	TTA L	870 GTT V	алл K	GGT G	R K	CYY Q	GGC G	TAT Y	GTT V	GCT A	CA P	900 CAA Q
TCG S	ATG M	ATG M	AAC N	GAT D	TTT F	GGT G	ATT I	ACG T	840 GTT V 930	GAA E	AAT N	CGA R	GAT D	TAC Y	r K	ACC T	TTT F	TTA L	870 GTT V 960	ала K	GGT G	R K	CAA Q	GGC G	TAT Y	gtt V	GCT A	P	900 CAA Q 990
TCG S GGT	ATG M PAAI	M M	AAC N TTG	GAT D GTG	TTT F	GGT G	ATT I GAT	ACG T	840 GTT V 930	GAA E TCT	AAT N GCC	CGA R TCT	GAT D TAT	TAC Y TTC	AAA K TTA	ACC T	F	tta L Ggt	870 GTT V 960 GCG	AAA K ATT	GGT G AAG	R R GCA	CAA Q GGT	GGC G	TAT Y GTA	GTT V ACG	GCT A GGC	P	900 CAA Q 990 GGT
TCG S GGT G	ATG M AAT N	ATG M TAT	AAC N TTG L	GAT D GTG V	TTT F GAG E	GGT G GGA G	ATT I GAT D	ACG T GCC A	840 GTT V 930 TCT S	GAA E TCT S	AAT N GCC A	CGA R TCT S	GAT D TAT Y	TAC Y TTC F	AAA K TTA L	ACC T GCC A	F F TCC	ITA L GGT	870 GTT 960 GCG A	AAA K ATT	GGT G AAG K	ала K GCA A	CAA Q GGT G	GGC G AAA K	TAT Y GTA V	GTT V ACG	GCT A GGC	P P	900 CAA Q 990 GGT G
TCG S GGT G	ATG M AAI N	ATG M TAI Y	N TTG L	GAT D GTG V	TTT F GAG E	GGT G GGA G	ATT I GAT D	ACG T GCC A	840 GTT 930 TCT S	GAA E TCT S	AAT N GCC A	CGA R TCT S	GAT D TAT Y	TAC Y TTC F	AAA K TTA L	ACC T GCC A	TTT F TCC S	L GGT G	870 GTT 960 GCG A 050	AAA K ATT I	GGT G AAG K	ала К GCA Л	CAA Q GGT G	GGC G AAA K	TAT Y GTA V	GTT V ACG T	GCT A GGC	P TT I	900 CAA Q 990 GGT G
тсс s GGT g	ATG M AAI N	M M TAI Y	AAC N TTG L	GAT D GTG V	TTT F GAG E	GGT G GGA G GAC	ATT I GAT D	ACG T GCC A 1 TTG	840 GTT 930 TCT S .020	GAA E TCT S	AAT N GCC A GAT	CGA R TCT S GTG	GAT D TAT Y	TAC Y TTC F	AAA K TTA L AAA	ACC T GCC A	TTT F TCC S	ITA L GGT G 1 GCA	870 GTT 960 GCG A 050	AAA K ATT I ATC	GGT G AAG K	AAA K GCA A TGG	CAA Q GGT G	GGC G XXXX K	TAT Y GTA V GAT	ACG	GCT A GGC G	P TT I 1	900 CAA Q 990 GGT G 080 GCC
TCG S GGT G XXX K	ATG M AAI N AAA K	TAI Y TCG	TTG L L L	GAT D GTG V CAA	GAG E GGC G	GGT G GGA G D	GAT I GAT D CGC R	GCC T GCC A 1 TTG L	840 GTT 930 TCT S .020 TTT F	GAA E TCT S GCC A	AAT N GCC A GAT D	CGA R TCT S GTG V	GAT D TAT Y TTG L	TAC Y TTC F GAA E	AAA K TTA L AAA K	ACC T GCC A ATG	TTT F TCC S	GGT G G G CA A	870 GTT 960 GCG A 050 AAA K	AAA K ATT I ATC	GGT G AAG K ACT T	AAA K GCA A TGG	CAA Q GGT G G G	GGC G AAA K CAG E	TAT Y GTA V GAT D	ACG T TTTT	GCT A GGC G ATT I	P TT I SAA	900 CAA Q 990 GGT G 080 GCC A
TCG S GGT G XXX	ATG M AAI N AAA K	M M TAI Y ATCG	TTG L ATC I	GAT D GTG V CAA	GAG E G G	GGT G G G G C A C D	GAT I GAT D CGC R	GCC A T T T T L 1	840 GTT 930 TCT 5 .020 TTT F	GAA E TCT S GCC A	AAT N GCC A GCC A	CGA R TCT S GTG V	GAT D TAT Y TTG L	TAC Y TTC F GAA E	AAA K TTA L AAA K	ACC T GCC A ATG	TTT F TCC S G G	ITA L GGT G L GCA J	870 GTT 960 GCG A 050 AAA K 140	AAA K ATT I ATC I	GGT G AAG K ACT T	AAA K GCA A TGG	CAA Q GGT G G	GGC G AAA K CAG E	TAT Y GTA V GAT D	ACG T TTTT	GCT A GGC. G ATT I	CCA P I I CAA Q 1	900 CAA Q 990 GGT G 080 GCC A 170
TCG S GGT AAA K GAG	ATG M AAI N K	ATCG M TAI Y ATCG	TTG L L L L L L L L L L L L L L L L L L	GAT D GTG V CAA Q	GAG G G G G G G	GGT G G G G G G G G G G G G G G G G G G	GAT I CAT D CGC R	ACG T GCC A 1 TTG L I GAT	840 GTT V 930 TCT S 020 TTT F .110 ATG	GAA E TCT S GCC A	AAT N GCC A GAT D	CGA R TCT S GTG V	CAT D TAT Y TTG L	TAC Y TTC F GAA E	AAA K L AAA K CCT	ACC T GCC A ATG M GAT	TTT F TCC S G G G G G G G G G G G G G G G G G G	TTA L GGT G SCA A 1 GCA	870 GTT 960 GCG A 050 AAA K 140 ATG	AAA K ATT I ATC I ACG	GGT G AAG K ACT T	AAA K GCA TGG W	CAA Q GGT G G G A CA	GGC G AAA K E ACC	TAT Y GTA V GAT D	ACG T TTT F	GCT A GCC G ATT I	P ATT I 2AA Q 1 SCCC	9900 CAA Q 9900 GGT G 0800 GCC A 1700 GAA
TCG S GGT G XXX K GAG E	ATG M AAT N AAAT K CAA Q	ATCO S	AAC N TTG L ATC I SCCG P	GAT D GTG V CAA Q CTA L	TTT F GAG E GGC G K	GGT G G G G C G G G G G	ATT I GAT D CCGC R CCGC R	ACG T GCCC A 1 TTTG L I GAT D	840 GTT V 930 TCT S 020 TTT F 110 CATG M	GAA E TCT S GCC A GAT D	AAT N GCC A GAT D XATG M	CGA R TCT S GTG V AAT N	GAT D TAT Y TTG L CAT H	TAC Y TTC F GAA E ATT I	AAA K TTA L AAA K CCT	ACC T GCCC A ATG M GAT D	TTT F TCC S G G G G G G G C G	ITA L GGT G L GCA A L GCA A	870 GTT: V 960 GCG A 050 AAA K 140 ATG M	AAA K ATT I ACG T	GGT G AAG K ACT T ATT I	AAA K GCA A TGG W	CAA Q GGT G G G G A CA T	GGC G AAA K GAG E ACC T	TAT Y GTA V GAT D GCT A	GTT V ACG T TTTT F	GCT A GCC G ATT I TTT F	P ATT I SCC A	900 CAA Q 990 GGT G 080 GCC A 170 GAA E
TCG S GGT G XXXX K GAG E	AATG M AAAT N AAAA K CAA Q	ATC M TAT Y ATCG S ATCC S	AAC N TTG L ATC I CCCG P	GAT D GTG V CAA Q CTA L	TTT F GAG E G G G AAA K	GGT G GGA G G G G G G G G	ATT I GAT D CCGC R CCGC R	ACG T GCCC A 1 TTTG L I GAT D	840 GTT V 930 TCT S 020 TTT F 110 ATG M 200	GAA E TCT S GCCC A GAT D	AAT N GCC A GAT D ATG M	CGA R TCT S GTG V AAT N	GAT D TAT Y TTG L CAT H	TAC Y TTC F GAA E ATT I	AAA K TTA L AAA K CCT P	ACC T GCC A ATG GAT D	TTT F TCC/ S GCG G GCG A	ITA L GGT G L GCA A I GCA A I	870 GTT: V 960 GCG A 050 AAA K 140 ATG M 230	AAA K ATT I ATC I ACG T	GGT G AAG K ACT T ATT I	AAA K GCA A TGG W GCA A	CAA Q GGT G G G ACA T	GGC G AAA K GAG E ACC T	TAT Y GTA V GAT D GCT A	GTT V ACG T TTTT F	GCT A GCC G ATT I TTT F	P ATT I SCC A I	900 CAA Q 990 GGT G 080 GCC A 170 GAA E 260
TCG S GGT G AAAA K CAG E GGA G	ATG M AAT N AAAT N K CAA Q AGAA E	AACA T	AAC N TTG L ATC I CCCG P SCCG V	GAT D GTG V CAA Q CTA L XATC I	GAG E GGC G AAA K CGC R	GGT G GGA G G G G G G G C G C G C C G C C C C	ATT I GAT D CGC R CGC R V X TI I	ACG T GCC A 1 TTG L I GAT D 1 TAT Y	840 GTT V 930 TCT S 020 TTT F 110 ATG M 200 N	GAA E TCT S GCCC A GGAT D TGG W	AAT N GCC A GAT D ATG M CGG R	CGA R TCT S GTG V AAT N GTA V	GAT D TAT Y TTG L CAT H AAA K	TAC Y TTC F GAA E ATT I GAA E	AAA K TTA L AAA K CCT P ACC T	ACC T GCC A ATG M GAT D GAC D	TTT F CCC S CCC G CCC R	TTA L GGT G L SCA J I GCA J I TTG L	870 GTT: 960 GCG A 050 AAA K 140 ATG M 230 ACA T	AAA K ATT I ACG T ACG A GCA A	GGT G AAG K ACT T ATT I ATG M	AAA K GCA A TGG W GCA A SGCA A	CAA Q GGT G G G G G A CA T A CO T	GGC G AAA K GAG E ACC T CAAA E	TAT Y GTA V GAT D GCT A TTG L	GTT V ACG T TTT F V TTA L CGT R	GCT A GGCC G ATT I TTT F AAA K	I SCCA 1 SCCCA 1 STC V	9900 CAA 990 GGT G 080 GCC A 170 GCAA E 260 GGGG G
TCG S GGT G AAAA K GAG G G G G G G	AAAA N AAAA K CAA Q AGAA E	ATC M TAT Y ATCG S ATCC S ATCC S ATCC S	AAC N L ATC I CCCG P V	GAT D GTG V CAA Q CAA L CTA L ATC I	GAG E GGC G C C C C C C C C C C C C C C C	GGT G GGAC D G G G G C G C G C C C C C C C C C C	ATT I GAT D CGC R CGC R V XATT I	ACG T GCC A 1 TTTG L I GAT D 1 TTAT Y 1	840 GTT V 930 TCT S 020 TTT F 110 ATG M 200 CAAC N 290	GAA E TCT S GCC A GAT D TGG W	AAT N GCC A GAT D ATG M CGG R	CGA R TCT S GTG V RAT N GTA V	GAT D TAT Y TTG L CAT H AAA K	TAC Y TTC F GAA E ATT I GAA E	AAA K L AAA K CCT P ACC T	ACC T GCC A ATG M GAT D GAC D	TTT F S GGG G G G G G G C G C G C G C G C G C	TTA L GGT G CA I GCA I TTG L	870 GTT: V 960 GCG: A 050 AAA: K 140 ATG ACA T 320	AAA K ATT I ACG T GCA A	GGT G AAG K ACT T ATT I ATG M	AAA K GCA A TGG W CGCA A SGCA A	CAA Q GGT G G G G G A CA T A C C T	GGC G XAAA K GAG E ACCC T GAA E	TAT Y GTA V GAT D GCI A TTG L	ACG T TTT F CTTA L CCGT R	GCT A GGC G ATT I TTT F AAA K	CA P I I CAA Q I SCCCA I STCCV I	900 CAA Q 990 GGT G 080 GCC A 170 GAA E 260 GGG G 350
TCG S GGT G AAAA K GAG G G G G G G G G G G	AATG M AAAT N AAAA K Q CAAA Q AGAAA	ATC M TAT Y ATCG S ATCC S ATCC S S GT/	AAC N TTG L ATC I CCCG P SCCG P V AGAA	GAT D GTG V CAA Q CTA L XATC I GAA	GAG E GAG G G AAAA K CGC R	GGT G GGA G G G G G G G G G G G G G G G	ATT I GAT D CGC R CGC R V V T I I GAA	ACG T GCCC A 1 TTTG L I GGT TAT Y 1 GGGG	840 GTT V 930 TCT S 020 TTT F 110 TTT F 200 CAAC N 290 GAA	GAA E TCT S GCC A GAT D TGG W	AAT N GCC A GAT D ATG M CGG R	CGA R TCT S GTG V AAT N GTA V XATI	GAT D TAT Y TTG L CAT H AAA K	TAC Y TTC F GAA E ATT I GAA E	AAA K TTA L AAA K CCT P ACC T	ACC T GCC A ATG GAT D GAC D	TTT F TCC S G G G G G G G G G C C TT	TTA L GGT GCA A 1 GCA A 1 TTG L 1 GCG	870 GTT: V 960 GCG A 050 AAA K 140 ATG ATG ATG M 320 TTA	AAA K ATT I ACG T GCA A GAA	GGT G AAG K ACT T ATT I ATG M AAC	AAA K GCA A TGG W GCA A CGCA A TTC	CAA Q GGT G G G A CA T A CAG	ссос С Алал К С Ассс Т С С Ассс С С Ассс	TAT Y GTA V GAT D GCT A TTG L	CGTT V ACG T TTTT F TTTA L CGT R	GCT A GGC G ATT I TTT F AAA K ATT	P ATT I I SOC A I STC V I SAA	900 CAA 990 GGT G 080 GCC A 170 GAA E 260 GGG G G 350 ACC
TCG S GGT G AAAA K GAG G G G A	ATG M AAAT N AAAA K Q AGAA E AGAA E	ATCG M TAT Y ATCG S ATCC S ATCC S ATCC S S T V C S T V	AAC N TTG L ATC I SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCC P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P SCCG P	GAT D GTG V CAA Q CTA L CTA L SATC I GAA E	GAG E GGC G AAA K CGC R CGC G	GGT G GGA G G G G G G G G G G G G G G G	ATT I CGAT D CGCC R V CGTA V I I GAA E	T GCCC A 1 TTG L I GAT D 1 TTAT Y I GGG G	840 GTT V 930 TCT S 020 TTT F 110 CATG M 200 CAAC N 290 GAA E	GAA E TCT S GCC A GAT D GAT D	AAT N GCCC A GAT D ATG M CGG R TTTI F	CGA R TCT S GTG V AAT N GTA V X ATI I	GAT D TAT Y TTG L CAT H AAA K	TAC Y TTC F GAA E ATT I GAA E ATT I	AAA K TTA L AAA K CCT P ACC T CAA Q	ACC T GCC A ATG M GAT D GAC D CCG P	TTT F TCC S C C C C C C C C C C C C C C C C C	TTA CGT G 1 CCA 1 CCA 1 CCA 1 1 CCA 1 1 CCA 1 1 CCA 1 1 CCA 1 1 CCA 1 1 CCA 1 1 CCA 1 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA 1 CCA CCA	870 GTT V 960 GCG A 050 A A A C A C A C A C A C A C A C A C A	AAAA K I ATC I ACG T GCA A GAAA E	GGT G XAG K ACT T XATT I ATG M AAC N	AAA K GCA A TGG W GCA A CGCA A TTC F	CAA Q GGT G G G G G G G G A CAG Q	ссос с алал к слас т сслас н	TAT Y GAT D GCI A TIG L SGCI A	GTT V ACG T TTT F SCGT R SCGAA E	GCT A GGC G ATT I TTT F AAA K ATT I	P ATT I I SCC A I SCC A I STC V I SAA E	900 CAA 990 GGT G 080 GCC A 170 GAA E 260 GGGG G 350 ACC T
TCG S GGT G AAAA K GAG G G G A A	AAAA MAAAA NAAAA K CAA Q AGAA E LGAC E	ATCG M TAT Y ATCG S ATCC S ATCC S T T V V	AAC N TTG L ATC I SCCG P SCCG P V V AGAA E	GAT D GTG V CAA Q CTA L CTA L CTA L CTA L	TTT F GAG E G G AAA K CCGC R C G G	GGT G GGAC D GGAC G G G G G G G G G G G G G G G G G	ATT I CGAT D CGC R V V ATT I SAAT E	ACG T GCCC A 1 TTTG L I GAT TAT Y I GCG G G 1	840 GTT V 930 TCT S 020 TTT F 110 ATG M 200 CAAC N 290 GAA E .380	GAA E TCT S GCC A GAT D U GAT D	AAT N GCC A GAT D ATG M CGG R TTTI F	CGA R TCT S GTG V AAT N GTA V X ATT I	GAT D TAT Y TTG L CAT H AAA K CCGG R	TAC Y TTC F GAA E ATT I GAA E ATT I I	AAA K TTA L AAA K CCT P ACC T CAA Q	ACC T GCC A ATG ATG D GAC D CCG P	TTT F TCC S C C C C C C C C C C C C C C C C C	TTA GGT G CA I GCA I I GCG A I GCG A I GCG I I I I I I I I I I I I I	870 GTT: 960 GCG A 050 AAA K 140 ATG ACA T 320 TTA L 410	AAA K I ATT I ACG T GCA A GAA E	GGT G AAG K ACT T ATT I ATG M AAC N	AAA K GCA TGG W GCA A CCA A CTTC F	CAA Q GGT G GGA G ACA T ACC T CAG Q GAT	GGC G AAA K GAG E ACCC T CGAA E CCAC H	TAT Y GAT D GCI A TTG L GCI A	GTT V ACG T TTT F CCGT R CCGT R	GCT A GGC G ATT I TTT F AAA K ATT I	P I I I I I I I I I I I I I I I I I I I	900 CAA 990 GGT G 080 GCC A 170 GAA E 260 GGG G 350 ACC T 440
TCG S GGT G G AAAA K GAG G G G A G G A TAI Y	AATG M AAAT N AAAA K CAA Q AGAA E AGAA E SAAC N	ATC M TAT Y ATCC S ATCC S ATCC S T V CGAI D	AAC N TTG L ATC I CCCG P V CCCG P V V V V V V AGAA E N V V V H	GAT D GTG V CAA Q CAA L CAA L SATC I GAA E CCT R	TTT F GAG E G G AAA K CGC R C G G C ATG M	GGT GGA GGA GGA GGA GGA GGA A I GGA A	ATT I GAT D CGC R CGC R V XATT I LGAA E NATG M	ACG T GCCC A 1 TTG L I I GAT D I TTAT Y I GGG G I I TTGT C	840 GTT V 930 TCT S 020 TTT F .110 CATG N .290 CAAC N .290 GAA E .380 TTT F	GAA E TCT S GCC A GAT D GAT D S TCA S	AAT N GGCC A GGAT D ATG R CGGG R TTT F TTTA L	CGA R TCT S GTG V AAT N GTA V CATT I I ATTI I	GAT D TAT Y TTG L CAT H AAAA K CCGG R R	TAC Y TTC F GAA E ATT I GAA E ATT I I TTA L	AAA K TTA L AAAA K CCT P ACC T CAA S	ACC T GCC A ATG GAT D GAC D CCG P AAT	TTT F S G G G G G G G G G G G G G G G C G C R C T T L X CAT T	TTA L GGT G CA I GCA I GCA E	870 GTT 960 GCG A 050 AAA K 140 ATG ACA T 320 ATA L 410 GTG V	AAA K ATT I ACG T GCA GCA E ACG T	GGT G AAG K ACT T ATT I ATG M AAC N I AAC	AAA K GCA TGG W GCA A CGCA A CGCA A TTC F	CAA Q GGT G GGA T ACCA T ACCA T CAG GAT D	GGC G AAA K AACC T AACC T CAAC H XCAAC H XCAAC P	TAT Y GAT D GCT A TTG L GCT A AAT N	GTT V ACG T TTT F C C TTTA R C C C TTTA C	GCT A GGCC G ATT I TTT F AAA K ATT I AAA T	CA P I I I I I I I I I I I I I I I I I I	900 CAA Q 990 GGT G 080 GCC A 170 GAA E 260 GGG G 350 C A 440 X K
TCG S GGT G G AAAA K GAG G G G G G C A X TAI Y	ATG M AAT N AAA K CAA C AGAA E AGAA E	ATC M TAT Y VTCG S VTCC S VTCC S V V CGAJ D	AAC N TTG L ATC I SCCG P V AGAN E CAC H	GAT D GTG V CAA Q CAA Q CAA L CAA L CAA L CAA L CAA CAA CAA CAA	TTT F GAG E G G G AAA K C C C C C C C C C C C C C C C C C	GGT G G G G G G G G G G G G G G G G G G	ATT I GAT D CCGC R V V XATT I GAA E M	ACG T GCCC A I TTG D I TTG G G G G G G G G G G G G G G G G G	840 GTT 930 TCT S 020 TTT F 110 ATG ATG ATG ATG ATG ATG ATG ATG ATG ATG	GAA E TCT S GCC A GAT D TGG W GAT D S	AAT N GCC A GAT D ATG R TTT F L	CGA R TCT S GTG V AAT N GTA V ATI I ATI I	GAT D TAT Y TTG L CAT H AAAA K CCGG R	TAC Y TTC F GAA E ATT I GAA E SATT I SATT I	AAA K L AAA K CCT P ACC T CAA Q S	ACC T GCC A M GAT D GAC D CCG P N	TTT F CCC S G G G G G G G G G G G G G G G C T L ACA T	TTA L GGT GCA 1 GCA 1 TTG A 1 GCG A 1 GCG A 1 1 GCG A 1 1 GCG A 1 1 GCG A 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	870 GTT V 960 GCG A 050 A A 30 A A C A T 320 TTA L 410 GTG V 500	AAA K ATT I ACG T GCA A GAA E ACG T	GGT G XAG K ACT T XATT I ATG M AAC N XATC I	AAA K GCA TGG W GCA A CTTC F TTTA L	CAA Q GGT G GGA T ACC T CAG Q GAT D	GGC G AAAA K GAG E AACC T CAAC H CCAAC H	TAT Y GAT D GGT A TTG L GGT A A AAT N	ACG T TTT F CCGT R C C C C C	GCT A GGC G ATT I TTT F AAA K ATT I AAA K ATT I VACC T	P I I I I I I I I I I I I I I I I I I I	900 CAA Q 990 GGT G 080 CCA 170 GGA 260 GGG G 350 ACC T 440 XAA K 530
TCG S GGT G G AAAA K GAG G G G G A TAI Y ACG	ATG M AAT N AAAT N CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C CAA C C CAA C C CAA C CAA C C CAA C C CAA C CAA C C CAA C C CAA C C C C C C C C C C C C C C C C C C C C	ATC M TAT Y VTCG S VTCC S VTCC S V V CGAJ D CCCC	AAC N TTG L ATC I SACT V AGAM E CAC H	GAT D GTG V CAA Q CAA Q CAA Q CAA Q CAA Q CAA Q CAA Q CAA Q CAA Q CAA Q CAA Q CAA Q CAA Q CAA Q CAA Q C CAA Q C C CAA Q C C C C	TTT F GAG G G G AAA K CCGC R C CCGC R C CCGC R C C C C C C C	GGT G GAC D GAC G G C G C C G C C C C C C C C C C C	ATT I GAT D CGC R CGC R V V V XATT I SGAO	ACG T GCCC A 1 TTG L I GAT D 1 TTAT T T C 1 TTG C 1 TTG C	840 GTT 930 TCT 5 020 TTT F 110 ATG ATG ATG ATG ATG ATG ATG ATG ATG ATG	GAA E TCT S GCCC A GAT D GAT D S GAT S	AAT N GCCCA GAT D ATG R TTT F L TTA	CGA R TCT S GTG V AAT I S ATI I I C	GAT D TAT Y TTG L CAT H AAAA K CCGG R CCGG R SCCGG	TAC Y TTC F GAA E ATT I GAA E ATT I SAGA	AAA K TTA L AAA K CCT P ACC T CAA Q TCG S TAA	ACC T GCC A M GAT D GAC D CCG P AAT N	TTT F S GCG G GCG A CGC R CTT L ACA T	TTA L GGT GCA 1 GCA 1 TTG A 1 GCG A 1 GCG A 1 1 GCG A 1 1 GCG A 1 1 GCG A 1 1 A 3 A	870 GTT: V 960 GCG A 050 A AAA K 140 ATG ACA T 3200 TTA L 410 GTG V 5500 AGG	AAA K ATT I ACG T GAA E ACG A A	GGT G AAG K ACT T ATT I ATG M AAC N SATC I CAG	AAAA K GCA A TGG W GCA A CGCA A TTCC F TTA L	CAA Q GGT G GGA T ACCA T CAG Q GAT D	GGC G AAAA K GAG E ACCC T CAC H CCAC H	TAT Y GAT D GGT D GGT L SGCT A N SGCT N N	GTT V ACG T TTT F CTTA R CGAA E CGAA CGAA C CGAA C C TTT	GCT A GCC G ATT I TTT F AAA K ATT I VACC T	CCA P I I I I I I I I I I I I I I I I I I	900 CAA Q 990 GGT G 080 GCC A 170 GCA E 260 GCG G 350 ACC T 440 XAA K 530

ATTGTGGCAGACTAAGCCCAACCGCT

FIG. 2. Nucleotide sequence of and deduced amino acid sequence encoded by P. haemolytica aroA.

Since we have shown that the PhaI-methylated hybrid plasmid consisting of plasmid pPhDaroACm^r joined with pD80 (Amp^r) from *P. haemolytica* could be used to transform *P.* haemolytica NADC-D60 (5), we investigated whether aroA mutants might arise after transformation with the hybrid plasmid. The hybrid plasmid was found, however, to be stable after multiple passages without selection, so no recombinant P. haemolytica could be detected. Since previous investigation demonstrated that the hybrid plasmid more efficiently transforms P. haemolytica when isolated from the homologous bacterium than when isolated from E. coli (5), an attempt was made to generate a suicide plasmid from the hybrid plasmid isolated from P. haemolytica. Linear and T4 ligase-treated relaxed circular pPh $\Delta aroACm^r$  plasmids were generated from the hybrid plasmid after restriction enzyme digestion. Neither version resulted in Cm^r colonies upon reintroduction into P. haemolytica. Although pPh $\Delta aroA\dot{C}m^r$  was treated with the Klenow fragment and deoxynucleoside triphosphates prior to treatment with T4 ligase, examination showed that most of the sample remained linear rather than circular. The results, then, are not totally unexpected, since there have been few reports of the successful establishment of linear DNA into bacteria (10, 16, 24).

Because initial selection on chloramphenicol has been inferior to selection on ampicillin in our laboratory (5), we decided to change the antibiotic resistance cassette in our replacement plasmid from Cm^r to Amp^r (5). A Sau3A-generated 2.2-kb fragment from pD80 from *P. haemolytica* which conferred ampicillin resistance was cloned into the BamHI site of pBC SK, resulting in pPhAmp^r. To demonstrate that pPhAmp^r dia not possess the pD80 origin of replication, pPhAmp^r was isolated from *E. coli* containing *Pha1* methyltransferase by methods described previously, CsCl purified, and introduced into *P. haemolytica* by electroporation. Since the *Pha1*-methylated plasmid did not confer ampicillin resistance to *P. haemolytica* NADC-D60, we concluded that the fragment encoding



FIG. 3. Construction of a *P. haemolytica aroA* mutant. The hybrid plasmid pPharoA⁻Amp^rpD70 shown above was successfully used to produce an *aroA* mutant.

β-lactamase did not contain the pD80 origin of replication. The 2.2-kb Amp^r fragment, made blunt, was used to insertionally inactivate *aroA* upon introduction into the unique *NdeI* site of *aroA*. The resulting plasmid, pPharoA⁻Amp^r (Fig. 3), after passage through *E. coli Pha*^r MTase failed to generate ampicillin-resistant colonies of *P. haemolytica*.

To increase the likelihood of selecting an *aroA* mutant arising by homologous recombination between inactivated *aroA* on the deletion plasmids and the *P. haemolytica* chromosome, we constructed a second hybrid plasmid. This hybrid construct joined a 4.2-kb *P. haemolytica* plasmid encoding streptomycin resistance (6), designated pD70, with the replacement plasmid pPharoA⁻Amp^r. Because pD70 may be unstable in *P. haemolytica* (4a), we hypothesized that the hybrid plasmid pPharoA⁻Amp^rpD70 also would be unstable in *P. haemolytica*. Thus, after repeated passages in medium containing ampicillin, a *P. haemolytica* clone transformed with pPharoA⁻Amp^rpD70 should eventually give rise to mutants via homologous recombination which express β-lactamase by means of chromosomally encoded Amp^r genes. And some of these mutants would be expected to have inactivated *aroA* genes.

The hybrid plasmid was constructed by joining HindIIIdigested pD70 with HindIII-digested pPharoA Ampr. The resultant hybrid plasmid, pPharoA⁻Amp^rpD70 (Fig. 3), was isolated from E. coli PhaIMtase, purified by standard methods, and introduced into P. haemolytica NADC-D60 by electroporation. Transformation efficiency of the hybrid plasmid yielded approximately  $10^1$  ampicillin-resistant colonies per  $\mu g$  of DNA. Eight Amp^r clones were grown overnight in Columbia broth containing 1 µg of ampicillin per ml. Chromosomal DNAs from the parental strain and from the Amp^r clones were digested with HindIII and analyzed by Southern blotting with P. haemolytica aroA, pBC SK, and pD70 radiolabeled probes. The results indicated that intact pPharoA-Amp^rpD70 was present in the Amp^r clones (data not shown). The eight Amp^r cultures were transferred to Columbia broth containing 1 µg of ampicillin per ml and cultured at 37°C. The bacteria were transferred to fresh media daily, and this process was continued for approximately 100 generations. The eight cultures were streaked for isolation without antibiotic selection, and a single colony of each was passed into Columbia broth containing either 1  $\mu$ g of ampicillin per ml or 1  $\mu$ g of chloramphenicol per ml. Two of the eight survived on the broth containing ampicillin; none surviving on chloramphenicol-containing broth. Passage from ampicillin-containing broth onto blood agar plates containing either ampicillin or chloramphenicol or streptomycin confirmed that the two clones were Amp^r, Cm^s Sm^s. Also, the two Amp^r clones were spread onto plates of chemically defined medium for P. haemolytica cultivation (23). This medium lacks the aromatic amino acid tryptophan. The parent strain grew on the defined medium, but the Amp' clones did not. Upon addition of tryptophan to the defined medium, growth of the Amp^r clones was comparable to that of



FIG. 4. Southern hybridization of genomic DNAs from the parental strain *P. haemolytica* NADC-D60 (lanes 1), the *aroA* mutant (lanes 2), and the hybrid plasmid pPharoA⁻Amp^rpD70 (lanes 3). All the DNAs used in the blots shown here were digested with *Hind*III. (A) Probed with *P. haemolytica aroA*; (B) probed with *P. haemolytica* Amp^r fragment; (C) probed with *P. haemolytica* pD70 plasmid; (D) probed with pBCSK. DNA was isolated from *P. haemolytica* NADC-D70 and run in lane 1 of blot C to demonstrate that if plasmid DNA was present in the bacteria it would also be present in our DNA preparations.

the parent strain. The *E. coli aroA* mutant AB2829 also required tryptophan to grow on the chemically defined medium for *P. haemolytica* cultivation. DNAs from the two colonies with Amp^r Cm^s Sm^s aroA mutant phenotypes were analyzed by Southern blotting. The results indicated that both had insertionally inactivated aroA genes. Moreover, Southern blotting also confirmed that both pD70 and pBC SK sequences were no longer present in the aroA mutants (Fig. 4).

The experimental approach that successfully produced an aroA mutant required repeated passage of P. haemolytica transformed with the hybrid plasmid pPharoA Amp^rpD70. Although this hybrid plasmid was able to replicate in P. haemolytica, improving the chance for recombination, its instability allowed recovery of plasmidless aroA mutants. The failure of the replacement plasmid alone to generate antibiotic-resistant colonies of P. haemolytica may be explained by the low transformation frequencies of PhaI-methylated plasmids which were insufficient to routinely produce mutants by the rare event of homologous recombination. In other bacteria, conjugative suicide vectors have been shown to be highly efficient for gene replacement constructions. For this reason, we constructed a derivative of pPharoA-AmprpD70 which contained mob (20), the P-type-specific recognition site for mobilization, inserted in the unique BamHI site of the polylinker. The hybrid plasmid was mobilized from E. coli S17-1 (20) with and without PhaI methyltransferase on a compatible vector. No P. haemolytica transconjugates were detected from donors lacking *PhaI* methyltransferase; approximately  $10^{-9}$  arose following matings with donors which contained PhaI methyltransferase. Plasmid recovered from the transconjugates apparently had undergone rearrangement, because their apparent molecular weights differed from that of the donor plasmid (data not shown).

To our knowledge, the work described here is the first report of site-directed gene replacement in *P. haemolytica*. Whether the *P. haemolytica aroA* mutant is attenuated is yet to be determined. Future work aimed at assessing the suitability of the *aroA* mutant as a live vaccine against pneumonic pasteurellosis in cattle and sheep is planned.

#### REFERENCES

- Ausubel, F. M., R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl. 1990. Current protocols in molecular biology. Greene Publishing and Wiley Interscience, New York.
- Azad, A. K., J. G. Coote, and R. Parton. 1992. Distinct plasmid profiles of *Pasteurella haemolytica* serotypes and the characterization and amplification in *Escherichia coli* of ampicillin-resistance plasmids encoding ROB-1 β-lactamase. J. Gen. Microbiol. 138: 1185–1196.
- 3. Bacon, G. A., T. W. Burrows, and M. Yates. 1950. The effects of the biochemical mutations on the virulence of *Bacterium typhosa*: the virulence of mutants. Br. J. Exp. Pathol. **31**:703–711.
- Bowe, F., P. O'Gaora, D. Maskell, M. Cafferkey, and G. Dougan. 1989. Virulence, persistence, and immunogenicity of *Yersenia entercolitica* O:8 *aroA* mutants. Infect. Immun. 57:3234–3236.
- 4a.Briggs, R. Personal observation.
- Briggs, R. E., F. M. Tatum, T. A. Casey, and G. H. Frank. 1994. Characterization of a restriction endonuclease, *PhaI*, from *Pasteurella haemolytica* serotype A1 and protection of heterologous

DNA by a cloned *PhaI* methyltransferase gene. Appl. Environ. Microbiol. **60**:2006–2010.

- Chang, Y. F., D. P. Ma, H. Q. Bai, R. Young, D. K. Struck, S. J. Shin, and D. H. Lein. 1992. Characterization of plasmids with antimicrobial resistant genes in *Pasteurella haemolytica* A1. J. DNA Seq. Map. 3:89–97.
- Collins, F. M. 1974. Vaccines and cell-mediated immunity. Bacteriol. Rev. 38:371–395.
- 8. Duncan, K., and J. R. Coggins. 1986. The *serC-aroA* operon of *Escherichia coli*. Biochem. J. 234:49–57.
- Friedman, A. H., S. R. Long, S. E. Brown, W. T. Buikema, and F. M. Ausubel. 1982. Construction of a broad host range cosmid cloning vector and its use in the genetic analysis of *Rhizobium* mutants. Gene 18:289–296.
- Hansen, E. J., J. L. Latimer, S. E. Thomas, M. Helminen, W. L. Albritton, and J. D. Radolf. 1992. Use of electroporation to construct isogenic mutants of *Haemophilus ducreyi*. J. Bacteriol. 174:5442–5449.
- Hoiseth, S. K., and B. A. D. Stocker. 1981. Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature (London) 291:238–239.
- Hoiseth, S. K., and B. A. D. Stocker. 1985. Genes aroA and serC of Salmonella typhimurium constitute an operon. J. Bacteriol. 163: 355–361.
- Homchampa, R. A., R. A. Strugnell, and B. Adler. 1992. Molecular analysis of the *aroA* gene of *Pasteurella multocida* and vaccine potential of a constructed *aroA* mutant. Mol. Microbiol. 23:3585– 3593.
- Liverelli, V., J. Peduzzi, and B. Joly. 1991. Sequence and molecular characterization of the ROB-1 β-lactamase from *Pasteurella haemolytica*. Antimicrob. Agents Chemother. 35:242–251.
- 15. Maniatis, T., E. F. Fritsch, and J. Sambrook. 1982. Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
- Micheletti, P. A., K. A. Sment, and J. Konisky. 1991. Isolation of a coenzyme M-auxotrophic mutant and transformation by electroporation in *Methanococcus voltae*. J. Bacteriol. 173:3414–3418.
- 17. O'Gaora, P., D. Maskell, D. Coleman, M. Cafferkey, and G. Dougan. 1989. Cloning and characterization of the *serC* and the *aroA* genes of *Yersenia enterocolitica*, and construction of an *aroA* mutant. Gene 84:23–30.
- Pittard, J., and B. J. Wallace. 1966. Distribution and function of genes concerned with aromatic amino acid biosynthesis in *Esche*richia coli. J. Bacteriol. 91:1494–1508.
- Roberts, R., D. Maskell, P. Novotny, and G. Dougan. 1990. Construction and characterization in vivo of *Bordetella pertussis* aroA mutants. Infect. Immun. 58:732-739.
- Simon, R., V. Prier, and A. Puhler. 1983. A broad host range mobilization system for *in vivo* genetic engineering: transposon mutagenesis in gram negative bacteria. Bio/Technology. 1:784– 791.
- Sost, D., and N. Amrhein. 1990. Substitution of Gly-96 to Ala in the 5-enolpyruvylshikimate 3-phosphate synthase of *Klebsella pneumoniae* results in a greatly reduced affinity for the herbicide glyphosate. Arch. Biochem. Biophys. 282:433–436.
- Verma, N. K., and A. A. Lindberg. 1991. Construction of aromatic dependent *Shigella flexneri* 2a live vaccine candidate strains: deletion mutations in the *aroA* and the *aroD* genes. Vaccine 9:6–9.
- 23. Wessman, G. E. 1966. Cultivation of *Pasteurella haemolytica* in a chemically defined medium. Appl. Microbiol. 14:597–602.
- 24. Zealy, G. R., S. M. Loosmore, R. K. Yacoob, S. A. Cockle, L. J. Boux, L. D. Miller, and M. H. Klein. 1990. Gene replacement in *Bordetella pertussis* by transformation with linear DNA. Bio/ Technology 8:1025–1029.